THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,329 | -23.1% | 154 | -7.8% | 0.00% | – |
| Q2 2023 | $1,728 | -10.0% | 167 | -5.6% | 0.00% | – |
| Q1 2023 | $1,920 | -67.2% | 177 | -66.0% | 0.00% | – |
| Q4 2022 | $5,846 | +16.9% | 521 | +15.8% | 0.00% | – |
| Q3 2022 | $5,000 | +25.0% | 450 | +2.0% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 441 | -10.7% | 0.00% | – |
| Q1 2022 | $5,000 | +66.7% | 494 | +59.9% | 0.00% | – |
| Q4 2021 | $3,000 | +200.0% | 309 | +99.4% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 155 | -3.1% | 0.00% | – |
| Q2 2021 | $2,000 | -71.4% | 160 | -55.3% | 0.00% | – |
| Q1 2021 | $7,000 | +600.0% | 358 | +336.6% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 82 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 82 | +39.0% | 0.00% | – |
| Q2 2020 | $1,000 | -80.0% | 59 | -70.5% | 0.00% | -100.0% |
| Q2 2018 | $5,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |